Bifidobacterium animalis subsp. lactis Bl-04, or B. lactis Bl-04, is one strain of bifidobacteria. Some papers write it as BL04. Trials have given it alone and mixed with other strains. Trial amounts are counts of live cells, in colony-forming units (CFU).
Terms and sources
- one strain
- See the NIH ODS line on how strains are named, in the section below.
- Some papers
- For example, Grubb et al., 2020.
- mixed with other strains
- Alone: for example, West et al., 2014. Mixed: for example, Tingö et al., 2022, with Bi-07, Lpc-37 and NCFM.
- colony-forming units (CFU)
- Three trials of Bl-04 alone gave 1, 2 and 20 billion CFU a day. See the NIH ODS lines on labels under Forms.
Bifidobacterium lactis Bl-04 in the body
Bl-04 is not a nutrient, and the body has no daily requirement for it. Its trials measure things such as antibodies in blood, gut bacteria and stool habits.
NIH ODS notes: "Probiotics are identified by their genus, species, and strain designation; some probiotics also receive subspecies names." For Bl-04, the genus is Bifidobacterium, the species animalis, the subspecies lactis and the strain Bl-04. Many papers shorten the name to Bifidobacterium lactis Bl-04. NIH ODS adds: "Probiotic products often contain microbial organisms from the genera Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, Escherichia, and Bacillus and from the family Lactobacillaceae." NCCIH notes: "The most common are bacteria that belong to groups called Lactobacillus and Bifidobacterium." It adds: "Different types of probiotics may have different effects." Other strains of the same subspecies include HN019, Bi-07 and B420.
Terms and sources
- NIH ODS notes
- NIH Office of Dietary Supplements, fact sheet for health professionals.
- Many papers
- For example, Paineau et al., 2008.
- NCCIH notes
- National Center for Complementary and Integrative Health, Probiotics: Usefulness and Safety.
- HN019, Bi-07 and B420
- Named with Bl-04 in an FDA GRAS notice, GRN 445. They are different strains from Bl-04.
A 2009 paper compared the complete genome of Bl-04 with DSM 10140, another strain of the same subspecies. It reports a high degree of conservation between the two genomes in size, organization and sequence. By its account, standard techniques such as pulsed-field gel electrophoresis cannot tell the two strains apart.
Terms and sources
- A 2009 paper
- Barrangou et al., Journal of Bacteriology, 2009. The first author worked for Danisco USA.
NIH ODS writes: "The International Scientific Association for Probiotics and Prebiotics defines probiotics as ‘live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.’" It adds: "However, not all foods and dietary supplements that are labeled as probiotics have proven health benefits."
Terms and sources
- NIH ODS writes
- ISAPP consensus statement of 2014, as quoted by NIH ODS.
On safety, NIH ODS notes: "Probiotics are unlikely to cause harm in healthy people, and side effects are usually minor." It adds: "However, the use of probiotics has been linked to a few cases of bacteremia, fungemia, and infections that have resulted in severe illness; most of these cases involved individuals who were severely ill or immunocompromised."
Terms and sources
- On safety
- The first paragraph of the Safety Considerations section of the NIH ODS fact sheet. The rest of the section describes case reports and hospital data.
- bacteremia, fungemia
- Bacteria or fungi in the blood (our explanation).
Under its heading on possible harm, NCCIH says: "Probiotics have an extensive history of apparently safe use, particularly in healthy people." It continues: "However, few studies have looked at the safety of probiotics in detail, so there’s a lack of solid information on the frequency and severity of side effects." NCCIH adds: "The risk of harmful effects from probiotics is greater in people with severe illnesses or compromised immune systems." "When probiotics are being considered for high-risk individuals, such as premature infants or seriously ill hospital patients, the potential risks of probiotics should be carefully weighed against their benefits." "Cases of severe or fatal infections have been reported in premature infants who were given probiotics, and the U.S. Food and Drug Administration (FDA) has warned health care providers about this risk." It also lists: "Possible harmful effects of probiotics include infections, production of harmful substances by the probiotic microorganisms, and transfer of antibiotic resistance genes from probiotic microorganisms to other microorganisms in the digestive tract." And: "Some probiotic products have been reported to contain microorganisms other than those listed on the label." "In some instances, these contaminants may pose serious health risks." NCCIH advises: "Don’t use probiotics as a reason to postpone seeing your health care provider about any health problem." It adds: "If you’re considering a probiotic dietary supplement, consult your health care provider first." It continues: "This is especially important if you have health problems." And: "Anyone with a serious underlying health condition should be monitored closely while taking probiotics."
Terms and sources
- possible harm
- The whole section, in four paragraphs, as NCCIH wrote it. Then two of the three points under "More To Consider".
Where Bifidobacterium lactis Bl-04 comes from
NIH ODS notes: "Some types of fermented foods, such as yogurt, are potential sources of beneficial microbes, though not all fermented foods that contain live cultures have probiotic microorganisms." It adds: "Probiotic microorganisms are also sometimes added to unfermented foods."
In trials, Bl-04 was given in capsules or added to yogurt.
Terms and sources
- in capsules or added to yogurt
- Capsules: Grubb et al., 2020. Yogurt: Zhang et al., 2021, whose results are not listed here.
Daily amounts and the upper limit
NIH ODS notes: "There are currently no formal recommendations for or against the use of probiotics in healthy people." It adds: "However, some expert bodies of health professionals provide guidance on the use of specific probiotic strains in people with certain health conditions." "These groups also offer guidance for clinicians and consumers on choosing probiotic products."
Terms and sources
- NIH ODS notes
- The first paragraph of the NIH ODS section "Probiotic Selection and Use".
In three trials of Bl-04 alone, daily amounts were 1, 2 and 20 billion CFU.
Terms and sources
- three trials of Bl-04 alone
- Grubb et al., 2020: 1 billion CFU a day. West et al., 2014: 2.0 billion CFU a day. Paineau et al., 2008: 20 billion CFU a day. The results of West and Paineau are not listed here.
United States
There is no US recommended daily amount for Bl-04. The National Academies have not set an upper limit for Bl-04.
NCCIH notes: "Government regulation of probiotics in the United States is complex." It adds: "Depending on a probiotic product’s intended use, the FDA might regulate it as a dietary supplement, a food ingredient, or a drug." FDA had no questions about a GRAS notice for Bl-04 and three other B. lactis strains in foods.
Terms and sources
- a GRAS notice
- GRN 445, Danisco USA; FDA letter of April 2013.
We counted 677 US labels that name Bl-04. On all 677, Bl-04 is one of several ingredients, most often inside a blend. No label lists Bl-04 as the only ingredient.
Terms and sources
- 677 US labels
- NIH Dietary Supplement Label Database, including products no longer sold. The code Bl-04, BL-04, Bl04 or BL 04 as a whole word in one ingredient or form entry. We counted these.
- most often inside a blend
- 640 list it in a row nested under another row, such as a blend. 12 name it only in another row's list of forms. 25 give it a row of its own.
665 of the 677 labels give no separate amount for Bl-04. 7 give milligrams, 26 mg or 200 mg per serving, and 5 give a count. Where a blend that holds Bl-04 gives its total as a count, the median is 12 billion per serving.
Terms and sources
- no separate amount
- 653 labels list Bl-04 in a row, nested or not, without an amount. 12 name it only in another row's list of forms.
- a count
- As written: 200,000,000 units on 2 labels; 340,000,000 organisms; 2,000,000,000 CFU; 9,000,000,000 organisms. Each is per serving, and a serving is not always a full day's amount.
- the median is 12 billion
- 45 labels, in CFU, organisms or viable cells. The count is for all strains in the blend together.
The name used most often is Bifidobacterium lactis Bl-04, on 217 labels. Statements on 52 labels call Bl-04 a trademark; 50 of them name DuPont.
Terms and sources
- used most often
- Counted by exact spelling, ignoring capitals. Next come Bifidobacterium animalis lactis Bl-04 on 161 labels and Bifidobacterium lactis (Bl-04) on 131. We checked the 30 most common names by eye.
- Statements on 52 labels
- Label statements in the same database. One example: "Bl-04 and Bi-07 are trademarks of DuPont." Another label names Danisco A/S. Another names International Flavors and Fragrances. We counted these.
Published studies of Bifidobacterium lactis Bl-04
Many Bl-04 trials tested it mixed with other strains. Five trials of Bl-04 alone gave everyone a vaccine or a virus, or counted illness episodes. Those trials are not listed here.
1 study in adults not chosen for a diagnosis: no difference between groups.
Not listed: a trial in which everyone also got a vaccine. Also not listed: trials in which volunteers were given a virus, and other reports from them. Also not listed: trials that counted illness episodes, and another report of one of them. Also not listed: another report of the listed trial. Also not listed: trials of products that mix Bl-04 with other strains.
Our one-line summary comes first. The original is on PubMed.
Show the study
Adults took Bl-04 or a dummy capsule for 4 weeks; gut symptom scores did not differ between groups.
Trial · 3 groups: Bl-04, Bl-04 with phages, dummy capsule; 66 finished. · 4 weeks · industry-funded
Grubb et al., Nutrients, 2020
Terms and sources
- Adults
- 68 healthy adults aged 18 to 65 took part. They were randomized to Bl-04, Bl-04 with a phage product, or a dummy capsule. 66 finished. Another report of this trial found no significant change in blood vessel tests or blood fats attributable to Bl-04.
- Bl-04
- One 15-mg capsule a day with 1 billion CFU. The paper writes the strain as BL04.
- gut symptom scores
- A digestive health questionnaire, a stool diary and stool bacteria. Group changes, adjusted for the start, did not differ significantly. Stool consistency was reported as percentages of people in each group; the authors state that no values were statistically different.
- a dummy capsule
- Rice maltodextrin. About 12% of all participants reported mild or moderate side effects; none were severe. The authors write that the Bl-04 group had the most side effects. The paper does not give the share for each group.
- industry-funded
- Funded by Deerland Enzymes. The funder provided "type organisms" (B. lactis, E. coli, phage mixture). It "approved the design of the study" but, the paper says, had no role in data collection, analysis or writing.
Study · Free full text · about 29 min to read
Our estimate at about 200 words a minute, from the PMC full text.
Study summary
Sixty-eight healthy adults aged 18 to 65 in Colorado were randomized into three groups. They took Bl-04, Bl-04 with a phage product or a dummy capsule. Each was one 15-mg capsule a day for 4 weeks. The Bl-04 capsule held 1 billion CFU. Two people left after the first visit; 66 finished. Changes in digestive questionnaire scores, adjusted for the start, did not differ significantly between groups. About 12% of all participants reported mild or moderate side effects; none were severe. The authors write that the Bl-04 group had the most side effects. Deerland Enzymes funded the trial.
Information, not a prescription. Do not start, stop or combine supplements or medicines on your own.